RXRX Q2 Loss Wider Than Expected, Revenues Rise Y/Y, Stock Down
Financial Performance: Recursion Pharmaceuticals reported a loss of 41 cents per share in Q2 2025, exceeding expectations, while total revenues increased by 33% year-over-year to $19.2 million, driven by a milestone payment from Sanofi. However, the company's shares fell 4.7% due to mixed results and rising R&D expenses.
Pipeline Developments: The company discontinued three drug candidates but is focusing on more promising ones like REC-4881 and REC-1245, with ongoing studies expected to yield data in the coming years. Additionally, they acquired Rallybio's stake in a joint venture for developing a new treatment for hypophosphatasia, which is set to enter phase I studies by late 2026.
Trade with 70% Backtested Accuracy
Analyst Views on IMCR
About IMCR
About the author
Immunocore Announces R&D Leadership Changes
- Executive Departure: Immunocore announced that Executive Vice President of R&D David Berman will leave the company on February 27, 2026, to take a role at another biotech firm, indicating a significant leadership transition for the company.
- Internal Promotions: The company is promoting current Chief Medical Officer Mohammed Dar and Head of Regulatory Sciences Mark Moyer to Executive Vice President roles, with expanded responsibilities for clinical development and regulatory strategies, aiming to enhance R&D efficiency by leveraging the existing leadership team.
- R&D Achievements: Dar has led clinical development since 2019, successfully advancing KIMMTRAK to regulatory approval, which is now approved in 39 countries, showcasing the company's strong capabilities in oncology immunotherapy.
- Strategic Commitment: CEO Bahija Jallal expressed confidence in the R&D team despite the executive changes, committing to continue advancing clinical programs to meet patient needs for transformative therapies.
Immunocore to Showcase at Upcoming Investor Events
Company Overview: Immunocore Holdings plc is a biotechnology company focused on developing immunomodulating medicines for cancer, infectious diseases, and autoimmune diseases, utilizing its ImmTAX platform for TCR bispecific immunotherapies.
Upcoming Conferences: The company will participate in the Guggenheim 2nd Annual Healthcare Innovation Conference on November 11, 2025, and the Jefferies London Healthcare Conference on November 19, 2025, with live webcasts available on their website.
Product Highlight: Immunocore's leading oncology therapy, KIMMTRAK, is approved for treating HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma in several countries, including the US and EU.
Contact Information: For inquiries, Immunocore provides contact details for communications and investor relations, including email addresses and phone numbers.